4:39 PM
 | 
Jan 04, 2019
 |  BioCentury  |  Finance

Longitude takes a spin with Cydan

Why Longitude funded Cydan's latest spinout to makeover an Ipsen asset

Longitude Capital's first foray into a Cydan Development Inc. spinout came Thursday when Cydan launched Tiburio Therapeutics Inc. to repurpose TBR-760 (formerly BIM-23A760) from Ipsen Group (Euronext:IPN; Pink:IPSEY), eight years after the compound's false start in acromegaly.

Longitude's Sandip Agarwala told BioCentury the mechanism of action that tripped up BIM-23A760 in acromegaly gives the dopamine-somatostatin chimeric molecule significant potential in non-functioning pituitary adenoma (NFPA).

"We really have a running start with this asset."

Sandip Agarwala, Longitude Capital

When Ipsen discontinued...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >